Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
Black Diamond Therapeutics (Nasdaq: BDTX) announces participation in the Cowen 42nd Annual Health Care Conference. Its CEO, David M. Epstein, Ph.D., will join a panel on lung cancer on March 9, 2022, at 9:10 a.m. ET. A live webcast of the discussion will be available on the company’s website, with a replay accessible for 30 days. Black Diamond is focused on developing novel MasterKey therapies for patients with genetically defined cancers, leveraging its MAP drug discovery engine to target oncogenic mutations.
- None.
- None.
CAMBRIDGE, Mass. and NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will participate in a panel discussion on lung cancer at the Cowen 42nd Annual Health Care Conference being held virtually on Wednesday, March 9, 2022 at 9:10 a.m. ET.
A live webcast of the panel discussion can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the panel discussion will also be available and archived on the site for 30 days.
About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies. Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data to predict and validate oncogenic mutations that promote cancer across tumor types as MasterKey mutations. Black Diamond discovers and develops selective MasterKey therapies against these families of oncogenic mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors:
Julie Seidel
investors@bdtx.com
For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com
FAQ
When will Black Diamond Therapeutics participate in the Cowen Health Care Conference?
Who is the CEO of Black Diamond Therapeutics?
How can I watch Black Diamond Therapeutics' panel discussion?
What is the focus of Black Diamond Therapeutics' research?
What is the significance of the MAP drug discovery engine?
